Lucid Diagnostics, a subsidiary of Pavmed, files a registration statement for its IPO


Pavmed subsidiary (NSDQ: PAVM) Lucid diagnostics announced that Lucid has publicly filed a registration statement related to an Initial Public Offering (IPO) proposal.

The number of common shares and the price range of the offering have not yet been determined, according to a press release. Lucid Diagnostics intends to list its common shares on the Nasdaq market under the symbol “LUCD”.

Cantor Fitzgerald & Co. and Canaccord Genuity LLC will act as co-book managers for the proposed offering. BTIG, LLC and Needham & Co., LLC will act as co-leads of the proposed offering.

In February of this year, PavMed announced that Lucid would transform into a separate public company “if favorable market conditions continue to hold up, whether through an initial public offering (IPO) or a business combination with an acquisition company specializing in the health sector. “

At the time of the planned spin-off announcement, the companies said Lucid’s new business initiative will accelerate the commercialization of its EsoGuard technology by targeting multiple sales and marketing channels and creating a network of EsoCheck operators to ensure sufficient testing capacity and geographic coverage.

EsoCheck with “Collect and Protect Technology” is designed to provide a less invasive, more efficient and cost effective alternative to endoscopic biopsies when managing patients with eosinophilic esophagitis (EoE). PavMed sees it as a way to replace endoscopy with a non-invasive device for patients with a disease requiring multiple and frequent invasive endoscopies with biopsies.

About John Tuttle

Check Also

Anne Wyllie, research scientist at YSPH, discusses the success of the SalivaDirect testing protocol

On July 28-29, researchers, industry professionals and public health leaders from around the world will …

Leave a Reply

Your email address will not be published.